116 related articles for article (PubMed ID: 28073132)
1. Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms.
Alhusseini M; Samantray J
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):267-269. PubMed ID: 28073132
[No Abstract] [Full Text] [Related]
2. [Alterations of thyroid function in cancer patients: a case of hypothyroidism during immunotherapy.].
Rossini G; Zuppi P; Ramponi S; Garufi C; Grillo LR; Baldelli R
Recenti Prog Med; 2023 Dec; 114(12):14e-17e. PubMed ID: 38031867
[TBL] [Abstract][Full Text] [Related]
3. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
4. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.
Ratcliffe MJ; Sharpe A; Midha A; Barker C; Scott M; Scorer P; Al-Masri H; Rebelatto MC; Walker J
Clin Cancer Res; 2017 Jul; 23(14):3585-3591. PubMed ID: 28073845
[No Abstract] [Full Text] [Related]
5. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Merryman RW; Kim HT; Zinzani PL; Carlo-Stella C; Ansell SM; Perales MA; Avigdor A; Halwani AS; Houot R; Marchand T; Dhedin N; Lescaut W; Thiebaut-Bertrand A; François S; Stamatoullas-Bastard A; Rohrlich PS; Labussière Wallet H; Castagna L; Santoro A; Bachanova V; Bresler SC; Srivastava A; Kim H; Pesek E; Chammas M; Reynolds C; Ho VT; Antin JH; Ritz J; Soiffer RJ; Armand P
Blood; 2017 Mar; 129(10):1380-1388. PubMed ID: 28073785
[TBL] [Abstract][Full Text] [Related]
7. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Noguchi T; Ward JP; Gubin MM; Arthur CD; Lee SH; Hundal J; Selby MJ; Graziano RF; Mardis ER; Korman AJ; Schreiber RD
Cancer Immunol Res; 2017 Feb; 5(2):106-117. PubMed ID: 28073774
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
[TBL] [Abstract][Full Text] [Related]
9. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.
Wanchoo R; Karam S; Uppal NN; Barta VS; Deray G; Devoe C; Launay-Vacher V; Jhaveri KD;
Am J Nephrol; 2017; 45(2):160-169. PubMed ID: 28076863
[TBL] [Abstract][Full Text] [Related]
10. Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.
Barnett R; Barta VS; Jhaveri KD
N Engl J Med; 2017 Jan; 376(2):191-192. PubMed ID: 28076715
[No Abstract] [Full Text] [Related]
11. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
12. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.
Kobayashi T; Iwama S; Yasuda Y; Okada N; Tsunekawa T; Onoue T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Goto M; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Kiyoi H; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Arima H
J Endocr Soc; 2018 Mar; 2(3):241-251. PubMed ID: 29600292
[TBL] [Abstract][Full Text] [Related]
13. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
14. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
Pollack RM; Kagan M; Lotem M; Dresner-Pollak R
Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
[No Abstract] [Full Text] [Related]
15. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors.
Lima Ferreira J; Costa C; Marques B; Castro S; Victor M; Oliveira J; Santos AP; Sampaio IL; Duarte H; Marques AP; Torres I
Cancer Immunol Immunother; 2021 Feb; 70(2):299-309. PubMed ID: 32712715
[TBL] [Abstract][Full Text] [Related]
18. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
[No Abstract] [Full Text] [Related]
20. Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature.
Brancatella A; Viola N; Brogioni S; Montanelli L; Sardella C; Vitti P; Marcocci C; Lupi I; Latrofa F
Eur Thyroid J; 2019 Jul; 8(4):192-195. PubMed ID: 31602361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
